NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

There’s much we don’t fully grasp until approval drops and the underlying facts come to light. I’ve laid out my reasoning—challenge, run with it, or reject it.

Consider this:

-- The MHRA’s adoption of the Decentralized Point-of-Care Manufacturing Framework uniquely aligns with NWBO's platform—no other company with a drug pending approval shares this compatibility.

-- DCVax-L’s indication was updated from glioblastoma to “cancer”, hinting at expanded therapeutic demand requiring a much larger commercial footprint.

-- The approval timeline, originally estimated at 150 days, has now stretched beyond 500. Add Linda Powers’ statement in the 10K: “The Company has been holding off on proceeding with the fabrication of the Flaskworks system until regulatory feedback is received.” That, to me, signals that feedback—expressed publicly in the form of MHRA’s framework—has likely arrived.

Am I absolutely certain? Hell no. But does this scenario hold water and seem reasonable? Hell yes.